Financial reports
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
23 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
Current reports
8-K
Entry into a Material Definitive Agreement
18 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Jun 23
8-K
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
30 May 23
8-K
Other Events
22 May 23
8-K
Entry into a Material Definitive Agreement
19 May 23
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
15 May 23
8-K
Entry into a Material Definitive Agreement
27 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
8-K
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding its GIP Antagonist NM-136 for Obesity
5 Apr 23
8-K
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
28 Mar 23
Registration and prospectus
25-NSE
Exchange delisting
8 Sep 23
424B5
Prospectus supplement for primary offering
15 Mar 23
424B3
Prospectus supplement
4 Aug 22
S-3
Shelf registration
28 Jul 22
S-8
Registration of securities for employees
22 Jun 22
S-8
Registration of securities for employees
23 Mar 22
424B5
Prospectus supplement for primary offering
31 Mar 21
424B5
Prospectus supplement for primary offering
30 Mar 21
424B5
Prospectus supplement for primary offering
11 Dec 20
424B5
Prospectus supplement for primary offering
10 Dec 20
Proxies
PRE 14A
Preliminary proxy
19 May 23
DEFA14A
Additional proxy soliciting materials
29 Sep 22
DEF 14A
Definitive proxy
2 Aug 22
PRE 14A
Preliminary proxy
22 Jul 22
DEFA14A
Additional proxy soliciting materials
13 May 22
DEF 14A
Definitive proxy
13 May 22
PRE 14A
Preliminary proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
12 May 21
DEF 14A
Definitive proxy
12 May 21
PRE 14A
Preliminary proxy
23 Apr 21
Other
EFFECT
Notice of effectiveness
5 Aug 22
CORRESP
Correspondence with SEC
2 Aug 22
UPLOAD
Letter from SEC
1 Aug 22
EFFECT
Notice of effectiveness
19 Oct 20
EFFECT
Notice of effectiveness
13 Oct 20
CORRESP
Correspondence with SEC
7 Oct 20
UPLOAD
Letter from SEC
7 Oct 20
UPLOAD
Letter from SEC
3 Sep 20
CORRESP
Correspondence with SEC
26 Aug 20
UPLOAD
Letter from SEC
20 Aug 20
Ownership
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
144
Notice of proposed sale of securities
21 Jul 23
144
Notice of proposed sale of securities
19 Jul 23
144
Notice of proposed sale of securities
21 Apr 23
4
Bethany Sensenig
21 Apr 23
4
Mark A Sirgo
31 Mar 23
4
YEHUDA MICHAEL RICE
31 Mar 23
4
LORIN K JOHNSON
31 Mar 23
4
Michael T. Constantino
31 Mar 23
4
Samantha Ventimiglia
31 Mar 23